Your request has been received.
We will send you more information as it becomes available.
Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.
This case study represents an individual clinician experience with and methodology for using EXPAREL.
Pacira BioSciences, Inc., recognizes that there are other methodologies for administering local anesthetics, as well as individual patient considerations, when selecting the dose for a specific procedure.
Please see Important Safety Information below and refer to the Full Prescribing Information.
Disclosure: Dr Valente is a paid consultant for Pacira BioSciences, Inc.
The recommended dose of EXPAREL for infiltration in adults is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg. The recommended dose of EXPAREL for patients aged 6 to <17 years old is 4 mg/kg, up to a maximum of 266 mg. The recommended dose of EXPAREL in adults for interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal is 133 mg. The recommended dose of EXPAREL in adults for adductor canal block is 133 mg (10 mL) admixed with 50 mg (10 mL) of 0.5% bupivacaine HCl, for a total volume of 20 mL.
EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.
Bupivacaine HCl (which is approved for use in patients aged 12 and older) may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physicochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.
ASSESSED THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY
In this procedure, Dr Valente determined that a total volume of 40 mL would be needed to cover the surgical site. She admixed 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 20 mL of 0.25% bupivacaine HCl. Bupivacaine HCl was added to provide early-onset analgesia and bridge the time to onset of the long-acting analgesia provided by EXPAREL.
Dr Valente determines the total volume of EXPAREL solution based on whether the mastectomy is unilateral or bilateral. For bilateral procedures, she usually admixes 20 mL of EXPAREL with 20 mL of 0.25% bupivacaine HCl and expands that with 20 mL of injectable normal saline for a total volume of 60 mL. This provides 30 mL of EXPAREL admixture per each breast.
DIVIDED INJECTATE INTO SYRINGES WITH NEEDLE SIZES APPROPRIATE FOR INFILTRATION (20- TO 25-GAUGE) AND PLANNED WHICH AREAS TO INFILTRATE WITH EACH INJECTION
For this procedure, Dr Valente used one 10-mL syringe with a 25-gauge, 1-inch needle, and refilled it with the remaining admixture to utilize the total volume of 40 mL when needed.
POSTMASTECTOMY
After performing the mastectomy, Dr Valente injected 1 to 2 mL of admixed EXPAREL® (bupivacaine liposome injectable suspension) circumferentially around the mastectomy anatomical boundaries and into the insertion of the pectoralis major muscle for a total volume of approximately 25 mL. She first palpated the ribs and injected directly on top of the rib into the muscle, then moved inferiorly along the serratus anterior muscle. She continued laterally toward the anterior border of the latissimus dorsi muscle and progressed superiorly below the clavicle.
Next, Dr Valente injected about 5 mL of admixed EXPAREL directly into the pectoralis major muscle and then lifted up the muscle and injected about 3 to 5 mL of the EXPAREL admixture into the space between the pectoralis major and minor muscles.
Finally, Dr Valente infiltrated 3 to 5 mL of the EXPAREL admixture around the drain site. This ensured that there is adequate analgesia to an area where many patients may experience postsurgical pain. She injected around the drain site and into the subcutaneous tissues to make sure there were no gaps in analgesic coverage.
In order to provide adequate analgesic coverage, Dr Valente infiltrates EXPAREL® (bupivacaine liposome injectable suspension) circumferentially around the mastectomy surgical site to create a field block. She uses anatomical landmarks to guide her placement of EXPAREL. Then, Dr Valente performs a PECS block by injecting EXPAREL between the pectoralis muscles to produce regional analgesia in the anterior wall of the chest. She also ensures to infiltrate EXPAREL around the drain site, which is an area where many patients may complain of postsurgical pain.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.